BAY-94-9392 Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This BAY-94-9392 Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 11 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: HOLD / OPTION
Decision memo
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
The central underwriting question is whether BAY-94-9392 can convert its Small molecule drug, Diagnostic radiopharmaceuticals profile and SLC7A11 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | BAY-94-9392 (query alias: BAY-94-9392) |
|---|---|
| Modality / target | Small molecule drug, Diagnostic radiopharmaceuticals; SLC7A11; SLC7A11 inhibitors, PET imaging |
| Highest global status | Phase 1 |
| Originator | Piramal Pharma Limited |
| Active developers | Piramal Pharma Limited, Bayer AG, The University of Texas MD Anderson Cancer Center |
The MCP disease footprint includes Bile Duct Neoplasms, Hepatocellular Carcinoma, Liver metastases. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05322135 | Early Phase 1 | Terminated | 3 | Primary endpoint not disclosed in English source |
| NCT04488094 | Phase 2 | Completed | 7 | Primary endpoint not disclosed in English source |
| NCT03824535 | Phase 2 | Completed | 15 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
18F-FSPG PET/CT and Integrated Biomarkers for Early Lung Cancer Detection in Patients With Indeterminate Pulmonary Nodules
Phase 2; n=15; evaluation: Not stated in English source. Reported fields: Other (Not Including Serious) Adverse Events = 0 Pts
18F-FSPG PET/MRI or PET/CT Imaging of Cardiac Sarcoidosis or Inflammation
Phase 2; n=45; evaluation: Not stated in English source. Reported fields: Number of Participants With 18F-FSPG Uptake on PET/MRI or PET/CT Fused Images Indicating Cardiac Involvement of Sarcoidosis = 2 Pts
PET Imaging of Lung Cancer and Indeterminate Pulmonary Nodules With 18F-FSPG
Phase 2; n=46; evaluation: Not stated in English source. Reported fields: FDG sensitivity(low and high) = 0.706 proportion, range 0 to 1, higher better (95%CI, 0.489 - 0.922)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
BAY-94-9392 addresses Bile Duct Neoplasms, Hepatocellular Carcinoma, Liver metastases. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug, Diagnostic radiopharmaceuticals—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned matched transaction record(s) under the scope “target-level comparable: SLC7A11.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: SLC7A11 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| No matched asset or comparable transaction returned. | |||
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Method for production of f-18 labeled glutamic acid derivatives”. The milestone feed surfaced a patent-application signal described as “New [F-18]-marked L-glutamic acids and L-glutamic acid derivatives (1), application thereof and method for their manufacture”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Therapeutic index and off-target toxicity
- Resistance biology and biomarker-defined patient selection
- Differentiation from established and emerging standards
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD / OPTION
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-11. Counts and status fields may change as source records update.
